Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 90kWORD 18k
20 February 2018
Question for written answer E-001017-18
to the Commission
Rule 130
Nicola Caputo (S&D) , Claudiu Ciprian Tănăsescu (S&D) , Momchil Nekov (S&D)

 Subject:  Boosting blood plasma collection in the EU
 Answer in writing 

In the EU today, more and more patients are being diagnosed with rare plasma‐related disorders, which leads to a growing clinical need for plasma‐derived medicinal products. The manufacture of plasma‐derived medicinal products for these life‐threatening health disorders is entirely dependent on having enough blood and plasma donations from citizens.

The current EU policy framework on blood and blood components has not ensured that donations are keeping pace with the increasing need for plasma‐derived medicinal products, thereby jeopardising patient access to care involving such therapies.

In 2017, the Commission published a roadmap for the evaluation of EU legislation on blood and blood components, which will be concluded by the end of 2018 and might possibly result in a revision of the EU Blood Directive.

If such a revision follows the evaluation process, does the Commission agree that the revised EU legal framework should include a wording which allows the Member States to establish national programmes for the collection of plasma through plasmapheresis, in the interests of boosting blood plasma collection in the EU, as well as of ensuring legal certainty for Member States?

Last updated: 6 March 2018Legal notice